User login
Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.
Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P = .02) and overall survival (OS; aHR 4.55; P = .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P = .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P = .02 and aHR 6.89; P < .01, respectively).
Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.
Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.
Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6
Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.
Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P = .02) and overall survival (OS; aHR 4.55; P = .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P = .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P = .02 and aHR 6.89; P < .01, respectively).
Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.
Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.
Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6
Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.
Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P = .02) and overall survival (OS; aHR 4.55; P = .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P = .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P = .02 and aHR 6.89; P < .01, respectively).
Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.
Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.
Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6